Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any hereditary spherocytosis in which the cause of the disease is a mutation in the SLC4A1 gene.
Features include always present findings: Increased red cell osmotic fragility, Spherocytosis, Red blood cell destruction (hemolytic anemia), and Increased immature red blood cells (reticulocytosis) and others. 7 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 3 | Red blood cell destruction (hemolytic anemia), Increased immature red blood cells (reticulocytosis), Enlarged spleen (splenomegaly) |
SLC4A1 function has not been fully characterized.
Hereditary spherocytosis type 4 is associated with mutations in the SLC4A1 gene on chromosome 17.
Genetic testing for SLC4A1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hereditary spherocytosis type 4 has been reported in the published literature.
Phenotype severity distribution: 5 always present features.
No clinical trials have been registered for hereditary spherocytosis type 4.
55 publications have been identified in PubMed for hereditary spherocytosis type 4. Research spans Case Report / Case Series (36%), Epidemiology / Natural History (18%), and Diagnostic / Biomarker (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 20 | 36% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 8:49 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Digestive system | 2 | Jaundice, Enlarged spleen (splenomegaly) |
Lab test results | 1 | Hyperbilirubinemia |
Disease patterns and progression
10 |
18% |
Testing and diagnosis research | 8 | 15% |
Clinical study results | 7 | 13% |
Research summaries | 6 | 11% |
Laboratory research | 4 | 7% |
Birke P (2026). [PMID: 42174500](https://pubmed.ncbi.nlm.nih.gov/42174500/). *BMC Infect Dis*. [Epidemiology / Natural History]
Shu H (2026). [PMID: 42126446](https://pubmed.ncbi.nlm.nih.gov/42126446/). *Ann Hematol*. [Epidemiology / Natural History]
Amarasingha D (2026). [PMID: 41857086](https://pubmed.ncbi.nlm.nih.gov/41857086/). *Scientific reports*. [Epidemiology / Natural History]
Mo Y (2026). [PMID: 41834204](https://pubmed.ncbi.nlm.nih.gov/41834204/). *Zhonghua er ke za zhi = Chinese journal of pediatrics*. [Diagnostic / Biomarker]
Zamora EA (2026). [PMID: 30969619](https://pubmed.ncbi.nlm.nih.gov/30969619/). *Unknown Journal*. [Review / Meta-Analysis]
de Wilde JRA (2026). [PMID: 41914049](https://pubmed.ncbi.nlm.nih.gov/41914049/). *British journal of haematology*. [Case Report / Case Series]
Vives-Corrons JL (2026). [PMID: 41596371](https://pubmed.ncbi.nlm.nih.gov/41596371/). *International journal of molecular sciences*. [Review / Meta-Analysis]
Adam AS (2026). [PMID: 41213817](https://pubmed.ncbi.nlm.nih.gov/41213817/). *International journal of laboratory hematology*. [Diagnostic / Biomarker]
Escribano Serrat S (2026). [PMID: 42124327](https://pubmed.ncbi.nlm.nih.gov/42124327/). *Cytometry B Clin Cytom*. [Diagnostic / Biomarker]
Qin Y (2026). [PMID: 41920367](https://pubmed.ncbi.nlm.nih.gov/41920367/). *Annals of hematology*. [Case Report / Case Series]